Editorials

Pregnancy Outcome in Inflammatory Arthropathies — Are Population Database Studies the Right Tool?
A. Polachek, L. Eder .................................................. 161

Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake
J.E. Pope ................................................................. 164

Review

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
S. Jamal, M. Hudson, A. Fifi-Mah, C. Ye .......................... 166

Rheumatoid Arthritis

Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in RA: A Systematic Review
C. Durand, M. Eldoma, D.A. Marshall, N. Bansback,
G.S. Hazlewood .......................................................... 176

Development and Validation of a MicroRNA Panel to Differentiate Between Patients with RA or SLE and Controls M.J. Ormseth, J.F. Solus, Q. Sheng, et al. .............. 188

A Population-level Analysis of the Differing Effects of RA and SpA on Peripartum Outcomes
S.O. Keeling, S.L. Bowker, A. Savu, P. Kaul ............................ 197

Spondyloarthritis

Prediction of AS in the HUNT Study by a Genetic Risk Score Combining 110 SNP of Genome-wide Significance
S. Rostami, M. Hoff, M.A. Brown, et al ............................ 204

Peripheral Manifestations in SpA and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study
C. López-Medina, A. Moltò, M. Dougados ........................... 211

Multimorbidity in AxSpA and Its Association with Disease Outcomes: Results from the AS Registry of Ireland Cohort G. Fitzgerald, P. Gallagher, F.D. O’Shea ........................... 218

Psoriatic Arthritis

Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasyovial Patterns in 100 Cases of Psoriatic Hand Dactylitis
N. Girolimetto, P. Macchioni, I. Tinazzi, et al ........................ 227

Systemic Lupus Erythematosus

Bacteremia in SLE in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes

Systemic Sclerosis

Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication

Worldwide Expert Agreement on Updated Recommendations for the Treatment of SSc
J.K. de Vries-Bouwstra, Y. Allanore, M. Matucci-Cerinic,
A. Babir-Gurman .......................................................... 249

Vasculitis

Insufficient Use of Corticosteroids without Immunosuppressants Results in Higher Relapse Rates in Takayasu Arteritis

Pulmonary Artery Involvement in Patients with Takayasu Arteritis
Y. He, N. Lv, A. Dang, N. Cheng ........................................ 264

Pediatric Rheumatology

Outcome Monitoring and Clinical Decision Support in Polyarticular JIA
L. Buckley, E. Ware, G. Kreher,
L. Wiater, J. Mehta, J.M. Burnham ....................................... 273

Contents continued on page xii
Osteoarthritis
Precision, Reliability, and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the OA Initiative

Other Arthritides
The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists
S. Mahmood, J.M. Hazes, P. Veldt, et al ................... 290

Images in Rheumatology
Targetoid-like Lesions in the Setting of SLE: A Case of Rowell Syndrome
J.M. Ward, J.N. Hess, L.S. Davis ......... 298

Correspondence
Menopause and Possible Effect on Association Between Age and Anticyclic Citrullinated Peptide Antibodies in Women At Risk of RA
D. Alpizar-Rodriguez, A. Finckh .............. 300

Reply
K.D. Deane, M.K. Demoruelle .................. 300

Letters
Renal Impairment in AxSpA: A Prevalent Condition to Consider
X. Michelena, C. Marco- Pascual, X. Gonzalez-Gimenez, X. Juanola .................. 301

The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in SLE
L.N. Dahal, R.N. Barker, F.J. Ward .................. 302

How Are Rheumatologists Managing Anticyclic Citrullinated Peptide Antibodies–positive Patients Who Do Not Have Arthritis?
K. Mankia, C. Briggs, P. Emery .............. 305

Meetings ............... iv